1. Home
  2. IMVT vs AMRX Comparison

IMVT vs AMRX Comparison

Compare IMVT & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMVT
  • AMRX
  • Stock Information
  • Founded
  • IMVT 2018
  • AMRX 2002
  • Country
  • IMVT United States
  • AMRX United States
  • Employees
  • IMVT N/A
  • AMRX N/A
  • Industry
  • IMVT Biotechnology: Biological Products (No Diagnostic Substances)
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMVT Health Care
  • AMRX Health Care
  • Exchange
  • IMVT Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • IMVT 2.7B
  • AMRX 2.9B
  • IPO Year
  • IMVT N/A
  • AMRX N/A
  • Fundamental
  • Price
  • IMVT $15.53
  • AMRX $9.79
  • Analyst Decision
  • IMVT Buy
  • AMRX Strong Buy
  • Analyst Count
  • IMVT 11
  • AMRX 4
  • Target Price
  • IMVT $33.88
  • AMRX $11.50
  • AVG Volume (30 Days)
  • IMVT 1.6M
  • AMRX 1.5M
  • Earning Date
  • IMVT 11-06-2025
  • AMRX 11-07-2025
  • Dividend Yield
  • IMVT N/A
  • AMRX N/A
  • EPS Growth
  • IMVT N/A
  • AMRX N/A
  • EPS
  • IMVT N/A
  • AMRX 0.01
  • Revenue
  • IMVT N/A
  • AMRX $2,852,914,000.00
  • Revenue This Year
  • IMVT N/A
  • AMRX $9.56
  • Revenue Next Year
  • IMVT N/A
  • AMRX $6.27
  • P/E Ratio
  • IMVT N/A
  • AMRX $911.06
  • Revenue Growth
  • IMVT N/A
  • AMRX 9.81
  • 52 Week Low
  • IMVT $12.72
  • AMRX $6.69
  • 52 Week High
  • IMVT $32.10
  • AMRX $10.34
  • Technical
  • Relative Strength Index (RSI)
  • IMVT 46.91
  • AMRX 62.50
  • Support Level
  • IMVT $16.08
  • AMRX $9.32
  • Resistance Level
  • IMVT $17.20
  • AMRX $10.34
  • Average True Range (ATR)
  • IMVT 0.79
  • AMRX 0.24
  • MACD
  • IMVT 0.09
  • AMRX -0.01
  • Stochastic Oscillator
  • IMVT 36.81
  • AMRX 51.75

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: